Sun Pharma Advanced Research Company (SPARC) has received Orphan Drug Designation from the US Food and Drug Administration (USFDA) for SCO-088 for the treatment of patients with Chronic Myeloid Leukemia (CML).
This is an important milestone in company’s journey to provide solution for patients who are not responding to the existing treatments available in the market. SCO-088 will fill the gap in the treatment of resistant CML.
SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
